To facilitate targeted drug delivery using nanodiamond (ND) vehicles, epirubicin-functionalized ND/lipid hybrids are coupled to epidermal growth factor receptor (EGFR) antibodies. The resulting particles mediate tumor regression, and markedly improve drug tolerance in a triplenegative breast cancer model in vivo. Furthermore, comprehensive biocompatibility analysis following intravenous ND administration indicate that the particles are well tolerated by mice. Further information can be found in the article by Dean Ho and co-workers on page 3532.
If you can't find a tool you're looking for, please click the link at the top of the page to "Go to old article view". Alternatively, view our Knowledge Base articles for additional help. Your feedback is important to us, so please let us know if you have comments or ideas for improvement.